Table 3 Responses by rituximab status... | American Society of Hematology

Table 3

Responses by rituximab status (refractory vs sensitive)

	n (%)	95% CI
Best response (rituximab-refractory, n = 30)
CRu	1 (3.3)	0.1-17.2
PR	2 (6.7)	0.8-22.1
SD*	19 (63.3)	43.9-80.1
PD	8 (26.7)	12.3-45.9
Best response (rituximab-sensitive, n = 23)
CR	1 (4.3)	0.1-21.9
CRu	2 (8.7)	1.1-28.0
PR	1 (4.3)	0.1-21.9
SD†	15 (65.2)	42.7-83.6
PD	4 (17.4)	5.0-38.8

	n (%)	95% CI
Best response (rituximab-refractory, n = 30)
CRu	1 (3.3)	0.1-17.2
PR	2 (6.7)	0.8-22.1
SD*	19 (63.3)	43.9-80.1
PD	8 (26.7)	12.3-45.9
Best response (rituximab-sensitive, n = 23)
CR	1 (4.3)	0.1-21.9
CRu	2 (8.7)	1.1-28.0
PR	1 (4.3)	0.1-21.9
SD†	15 (65.2)	42.7-83.6
PD	4 (17.4)	5.0-38.8

Refractory patients relapsed within 6 months of rituximab; sensitive patients relapsed more than 6 months after rituximab therapy.

Includes 6 with SD > 6 months.

Includes 5 with SD > 6 months.